Efficacy and predictors of response to inhaled corticosteroid treatment for chronic cough
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Inhaled corticosteroids (ICS) are a treatment of choice for eosinophilic airway diseases, but their efficacy for other causes of chronic cough is controversial. Methods: We conducted a prospective observational study to determine the ICS efficacy and clinical predictors of response to ICS in patients with upper airway cough syndrome (UACS) or unexplained chronic cough (UCC). Sixty-eight patients with UACS and 33 patients with UCC (duration of cough ≥ 8 weeks) were treated with ICS: 250 μg of fluticasone propionate or 400 μg of budesonide twice a day at physician’s discretion. They were followed after 2 weeks to assess persistent cough which was measured as 0% to 100% compared with baseline cough frequency. Results: The median grade of persistent cough after 2-week ICS treatment was 40% (interquartile range [IQR], 10 to 70) in UACS and was 50% (IQR, 20 to 70) in UCC. The only adverse event was infrequent, mild hoarse voice (five UACS and one UCC). Long duration of cough (≥ 52 weeks) and cough not aggravated by cold air exposure were predictors of a poorer response to short course ICS treatment (logistic regression analysis, p = 0.018 and p = 0.031, respectively). However, prolonged treatment with ICS more than 2 weeks was more effective in patients with long cough duration (≥ 52 weeks). Conclusions: Short course ICS treatment has modest efficacy on UACS and UCC without significant adverse events. Duration of cough and cough triggered by cold air exposure were the clinical factors associated with ICS response. Extended treatment with ICS may be beneficial in patients with long duration of cough.
Abstract
Background/Aims: Inhaled corticosteroids (ICS) are a treatment of choice for eosinophilic airway diseases, but their efficacy for other causes of chronic cough is controversial. Methods: We conducted a prospective observational study to determine the ICS efficacy and clinical predictors of response to ICS in patients with upper airway cough syndrome (UACS) or unexplained chronic cough (UCC). Sixty-eight patients with UACS and 33 patients with UCC (duration of cough ≥ 8 weeks) were treated with ICS: 250 μg of fluticasone propionate or 400 μg of budesonide twice a day at physician’s discretion. They were followed after 2 weeks to assess persistent cough which was measured as 0% to 100% compared with baseline cough frequency. Results: The median grade of persistent cough after 2-week ICS treatment was 40% (interquartile range [IQR], 10 to 70) in UACS and was 50% (IQR, 20 to 70) in UCC. The only adverse event was infrequent, mild hoarse voice (five UACS and one UCC). Long duration of cough (≥ 52 weeks) and cough not aggravated by cold air exposure were predictors of a poorer response to short course ICS treatment (logistic regression analysis, p = 0.018 and p = 0.031, respectively). However, prolonged treatment with ICS more than 2 weeks was more effective in patients with long cough duration (≥ 52 weeks). Conclusions: Short course ICS treatment has modest efficacy on UACS and UCC without significant adverse events. Duration of cough and cough triggered by cold air exposure were the clinical factors associated with ICS response. Extended treatment with ICS may be beneficial in patients with long duration of cough.
참고문헌 (31)
- Irwin RS, "The diagnosis and treatment of cough", N Engl J Med, 343, pp.1715~1721 (2000)
- Wynder EL, "Epidemiology of persistent cough", Am Rev Respir Dis, 91, pp.679~700 (1965)
- French CL, "Impact of chronic cough on quality of life", Arch Intern Med, 158, pp.1657~1661 (1998)
- Schappert SM, "Ambulatory medical care utilization estimates for 2007", Vital Health Stat, 169, pp.1~38 (2011)
- Irwin RS, "Chronic persistent cough in the adult : the spectrum and frequency of causes and successful outcome of specific therapy", Am Rev Respir Dis, 123, pp.413~417 (1981)
- McGarvey LP, "Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol", Thorax, 53, pp.738~743 (1998)
- McGarvey LP, "Cough. 6: Which investigations are most useful in the diagnosis of chronic cough?", Thorax, 59, pp.342~346 (2004)
- McGarvey L, "The difficult-to-treat, therapy-resistant cough: why are current cough treatments not working and what can we do?", Pulm Pharmacol Ther, 26, pp.528~531 (2013)
- Birring SS, "Controversies in the evaluation and management of chronic cough", Am J Respir Crit Care Med, 183, pp.708~715 (2011)
- Chang AB, "Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux", BMJ, 332, pp.11~17 (2006)
- Tanaka S, "Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough", Thorax, 51, pp.810~814 (1996)
- Pizzichini MM, "Nonasthmatic chronic cough : no effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia", Can Respir J, 6, pp.323~330 (1999)
- Ponsioen BP, "Efficacy of fluticasone on cough : a randomised controlled trial", Eur Respir J, 25, pp.147~152 (2005)
- Chaudhuri R, "Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough", J Allergy Clin Immunol, 113, pp.1063~1070 (2004)
- Lee SY, "Airway inflammation as an assessment of chronic nonproductive cough", Chest, 120, pp.1114~1120 (2001)
- Boulet LP, "Airway inflammation in nonasthmatic subjects with chronic cough", Am J Respir Crit Care Med, 149, pp.482~489 (1994)
- Chai H, "Standardization of bronchial inhalation challenge procedures", J Allergy Clin Immunol, 56, pp.323~327 (1975)
- Pin I, "Use of induced sputum cell counts to investigate airway inflammation in asthma", Thorax, 47, pp.25~29 (1992)
- Cox G, "A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers", Chest, 115, pp.1271~1277 (1999)
- Everett CF, "Chronic persistent cough in the community : a questionnaire survey", Cough, 3, pp.5~ (2007)
- Gibson P, "Treatment of unexplained chronic cough : CHEST Guideline and Expert Panel Report", Chest, 149, pp.27~44 (2016)
- Pavord ID, "Management of chronic cough", Lancet, 371, pp.1375~1384 (2008)
- Bolser DC, "Older-generation antihistamines and cough due to upper airway cough syndrome (UACS): efficacy and mechanism", Lung, (186 Suppl 1), pp.S74~S77 (2008)
- Poe RH, "Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol", Chest, 95, pp.723~728 (1989)
- Curley FJ, "Cough and the common cold", Am Rev Respir Dis, 138, pp.305~311 (1988)
- Ribeiro M, "High-dose inhaled beclomethasone treatment in patients with chronic cough : a randomized placebo-controlled study", Ann Allergy Asthma Immunol, 99, pp.61~68 (2007)
- 한보람, "만성 특발성 기침에 대한 흡입 스테로이드의 치료 효과", Tuberculosis and Respiratory Diseases, 67(5), pp.422~429 (2009), 대한결핵및호흡기학회
- Bardin PG, "Absence of pulmonary aspiration of sinus contents in patients with asthma and sinusitis", J Allergy Clin Immunol, 86, pp.82~88 (1990)
- Millqvist E, "TRP channels and temperature in airway disease-clinical significance", Temperature(Austin), 2, pp.172~177 (2015)
- Khalid S, "Transient receptor potential vanilloid 1(TRPV1)antagonism in patients with refractory chronic cough : a double-blind randomized controlled trial", J Allergy Clin Immunol, 134, pp.56~62 (2014)
- Antonicelli L, "Is ethanol-induced bronchospasm an inflammation-driven event?", Allergy, 61, pp.270~271 (2006)